Drug Analysis Service and Cannabis Laboratory

Health Canada’s Drug Analysis Service and Cannabis Laboratory analyze drugs and substances submitted by Canadian law enforcement and public health officials.

  • Last updated: 2024-04-12

On this page

Drug Analysis Service Publications

At-a-glance reports

New and emerging drug threats in Canada: Fentanyl precursors

New and emerging drug threats in Canada: Fentanyl precursors New

The aim of this report is to describe trends in fentanyl precursor identifications in Canada, highlighting changes in precursor use, regulatory actions, and evidence of domestic synthetic opioid production to inform public health and enforcement responses.

At-a-glance: New psychoactive substances in Canada – 2024

At-a-glance: New psychoactive substances in Canada – 2024 New

The aim of this report is to describe NPS that emerged in Canada in 2024 based on samples submitted to DAS by law enforcement and public health officials.

At-a-glance: New psychoactive substances in Canada – 2023

At-a-glance: New psychoactive substances in Canada – 2023

The aim of this report is to describe new psychoactive substances that emerged in Canada in 2023 based on samples submitted to the Drug Analysis Service by law enforcement agencies and public health partners.

At-a-glance: New psychoactive substances in Canada – 2022

At-a-glance: New psychoactive substances in Canada – 2022

The aim of this report is to describe new psychoactive substances that emerged in Canada in 2022 based on samples submitted to the Drug Analysis Service by law enforcement agencies and public health partners.

At-a-glance: The emergence of Nitazenes and Brorphine in Canada since 2019

At-a-glance: The emergence of Nitazenes and Brorphine in Canada since 2019

This report aims at presenting the result of a pilot project based on a collaborative work between the Drug Analysis Service, the Canada Border Services Agency (CBSA) and the Royal Canadian Mounted Police (RCMP) related to Nitazenes and Brorphine in order to draw a more complete picture of the situation in Canada.

At-a-glance: Newly reported psychoactive substances in Canada 2020-2021

At-a-glance: Newly reported psychoactive substances in Canada 2020-2021

The aim of this report is to describe new psychoactive substances which emerged in Canada since 2020.

In Focus reports

In Focus: The Emergence of Opioids in Canada

In Focus: The Emergence of Opioids in Canada New

This In Focus report outlines the trends observed in the opioid supply in Canada since 2012 based on samples submitted to the DAS by law enforcement and public health officials.

Infosheet

Emergence of Desalkylgidazepam, a novel benzodiazepine in Canada

Emergence of Desalkylgidazepam, a novel benzodiazepine in Canada New

This short report provides quick statistics on Desalkylgidazepam, the most identified new psychoactive substance in Canada in 2022 based on samples submitted to the Drug Analysis Service by law enforcement agencies and public health partners.

Spotlight reports

Spotlight : The evolution of Fentanyl in Canada over the past 11 years

Spotlight: The evolution of Fentanyl in Canada over the past 11 years

The aim of this spotlight report is to characterize trends in Fentanyl identifications across Canada since 2012 and draw a more comprehensive picture of Fentanyl in Canada based on exhibits seized and submitted to the Drug Analysis Service for analysis by law enforcement agencies.

Spotlight : The emergence of Xylazine in Canada

Spotlight: The emergence of Xylazine in Canada

The aim of this spotlight report is to characterize trends in Xylazine identifications across Canada since 2012 and draw a more comprehensive picture of Xylazine in Canada based on exhibits seized and submitted to the Drug Analysis Service for analysis by law enforcement agencies.

Cannabis Laboratory Publications

Cannabis Data Gathering Program: A comparison of legal and illegal dried cannabis products

Cannabis Data Gathering Program: A comparison of legal and illegal dried cannabis products

The Cannabis Data Gathering Program (the Program), launched in 2023 by Health Canada's Cannabis Laboratory, helps Health Canada collect information on the composition and quality of cannabis products available in Canada. The Program projects provide new data on cannabis where information may be limited, providing new evidence about potential risks and emerging trends.

Did you find what you were looking for?

What was wrong?

Answers to frequently asked questions can be found in the Understanding the data section!

(Don’t include any personal information. Note that you will not receive a reply.)
Maximum 300 characters

Thank you for your feedback

Date modified: